Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-11-08FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for granisetron hydrochloride (generic) from Mylan Institutional LLC.
-
FDA approval · 2016-11-08FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approves a supplemental application for granisetron hydrochloride from Mylan Institutional LLC, expanding access for this generic antiem…
-
CLINICAL_TRIALS research · 2016-10-14Clinical Trial Update: Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting [Phase 3]
Phase 3 clinical trial update evaluating aprepitant for the prevention of chemotherapy-induced nausea and vomiting; current status is UNKNOW…
-
FDA approval · 2016-09-28FDA Approved: APREPITANT — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for aprepitant filed by Sandoz Inc., updating the regulatory status for the drug.
-
FDA approval · 2016-08-09FDA Approved: SUSTOL — Original Application (Heron Therapeutics, Inc.)
FDA approved SUSTOL (granisetron) from Heron Therapeutics via an original NDA for prevention of chemotherapy-induced nausea and vomiting in …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2016-07-22Clinical Trial Update: Acupuncture for Chemical Therapy Induced Nausea and Vomiting [NA]
The clinical trial update indicates that the Beijing University of Chinese Medicine study on acupuncture for chemotherapy-induced nausea and…
-
FDA approval · 2016-07-01FDA Approved: DRONABINOL — Original Application (Wellhouse Pharma, LLC)
FDA approved dronabinol under an original NDA submitted by Wellhouse Pharma, LLC.
-
FDA approval · 2016-06-09FDA Approved: FOSAPREPITANT — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fosaprepitant from Fresenius Kabi USA, LLC under an Original Application (ANDA) to prevent chemotherapy-induced nausea and vomi…
-
CLINICAL_TRIALS trial_result · 2016-06-03Clinical Trial Update: Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting [Phase 2]
The Phase 2 clinical trial evaluating an Iranian traditional medicine remedy for chemotherapy-induced nausea and vomiting has completed.
-
CLINICAL_TRIALS trial_result · 2016-05-25Clinical Trial Update: Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors [Phase 2]
Phase 2 trial evaluating fosaprepitant plus a 5-HT3 receptor antagonist and dexamethasone for chemotherapy-induced nausea and vomiting in pa…
-
CLINICAL_TRIALS research · 2016-05-12Clinical Trial Update: Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Cancer [NA]
This clinical trial update describes a study using designed music narratives to reduce chemotherapy-related side effects in children aged 7-…
-
FDA label_change · 2016-04-22FDA Approved: VARUBI — Supplemental Application (TerSera Therapeutics LLC)
FDA approved a supplemental application for VARUBI (rolapitant) submitted by TerSera Therapeutics LLC to update the product label.
-
FDA approval · 2016-04-21FDA Approved: PALONOSETRON — Original Application (NorthStar Rx LLC)
FDA approved NorthStar Rx LLC's palonosetron as an original application (ANDA201533) for preventing postoperative and chemotherapy-induced n…
-
CLINICAL_TRIALS trial_result · 2016-04-15Clinical Trial Update: Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail [NA]
The document notes the completion of a cross-over clinical trial evaluating acupuncture for chemotherapy-induced nausea and vomiting. No res…
-
FDA approval · 2016-04-12FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for AKYNZEO (netupitant and palonosetron) from Helsinn Therapeutics (U.S.), Inc., expanding the …
-
FDA approval · 2016-04-04FDA Approved: VARUBI — Supplemental Application (TerSera Therapeutics LLC)
FDA approved a supplemental application for VARUBI (rolapitant) submitted by TerSera Therapeutics LLC.
-
CLINICAL_TRIALS trial_result · 2016-03-16Clinical Trial Update: Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting [Phase 2]
Phase 2 clinical trial evaluating ginger as an adjunctive prophylaxis for chemotherapy-induced nausea and vomiting. The study is completed.
-
FDA approval · 2016-03-03FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC.)
FDA approved a supplemental application for ondansetron hydrochloride submitted by Chartwell RX, LLC as an ANDA amendment.
-
FDA approval · 2016-03-01FDA Approved: POSFREA — Original Application (Avyxa Pharma, LLC)
The FDA approved POSFREA (palonosetron) from Avyxa Pharma, marking the original approval of this antiemetic for prevention of chemotherapy-i…
-
FDA approval · 2016-02-28FDA Approved: ONDANSETRON — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's supplemental application for ondansetron (ondansetron).
-
FDA approval · 2016-02-01FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approves a supplemental application for EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS research · 2016-01-12Clinical Trial Update: Complementary Effect of Reflexology on Chemotherapy-Induced Nausea and Vomiting [Phase 2]
A Phase 2 clinical trial evaluates whether reflexology can reduce chemotherapy-induced nausea and vomiting. The current status is UNKNOWN.
-
FDA approval · 2015-12-17FDA Approved: EMEND — Original Application (Merck Sharp & Dohme LLC)
FDA approved EMEND (aprepitant) from Merck as the original application for prevention of acute and delayed chemotherapy-induced nausea and v…
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy [Phase 3]
Phase 3 safety and efficacy study of rolapitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately …
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy [Phase 3]
Phase 3 trial evaluating rolapitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemo…